These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15968005)
1. Report of specific cardiovascular outcomes of the ADVANTAGE trial. Braunstein N; Polis A Ann Intern Med; 2005 Jul; 143(2):158-9. PubMed ID: 15968005 [No Abstract] [Full Text] [Related]
2. Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen. Ann Intern Med; 2003 Oct; 139(7):I29. PubMed ID: 14530248 [No Abstract] [Full Text] [Related]
3. Tolerability of rofecoxib versus naproxen. Rusche JM Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197028 [No Abstract] [Full Text] [Related]
4. Tolerability of rofecoxib versus naproxen. Jenkinson ML Ann Intern Med; 2004 Jun; 140(12):1059-60; author reply 1060. PubMed ID: 15197027 [No Abstract] [Full Text] [Related]
5. Tolerability of rofecoxib versus naproxen. Hanauer LB Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197026 [No Abstract] [Full Text] [Related]
6. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
8. Is rofecoxib safer than naproxen? Adelman A J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204 [No Abstract] [Full Text] [Related]
9. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Lisse JR; Perlman M; Johansson G; Shoemaker JR; Schechtman J; Skalky CS; Dixon ME; Polis AB; Mollen AJ; Geba GP; Ann Intern Med; 2003 Oct; 139(7):539-46. PubMed ID: 14530224 [TBL] [Abstract][Full Text] [Related]
10. A world without Vioxx: to COX-2 or not to COX-2? Simon LS; Strand V Cleve Clin J Med; 2004 Nov; 71(11):849-50, 852, 854 passim. PubMed ID: 15570734 [No Abstract] [Full Text] [Related]
12. Discontinuation of Vioxx. Kim PS; Reicin AS Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669 [No Abstract] [Full Text] [Related]
13. Life after Vioxx: the clinical implications. Fortun PJ; Hawkey CJ Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854 [No Abstract] [Full Text] [Related]
14. Increased risk of cardiovascular events with coxibs and NSAIDs. Emery P; Moore A; Hawkey C Lancet; 2005 Apr 30-May 6; 365(9470):1538. PubMed ID: 15866301 [No Abstract] [Full Text] [Related]
15. Increased risk of cardiovascular events with coxibs and NSAIDs. Scott DG; Watts RA Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299 [No Abstract] [Full Text] [Related]
16. Coxibs and cardiovascular disease. Fitzgerald GA N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192 [No Abstract] [Full Text] [Related]
17. [By what means does the rheumatic patient with gastrointestinal risks fare best?]. Einecke D MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040 [No Abstract] [Full Text] [Related]
19. The lessons of Vioxx--drug safety and sales. Waxman HA N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862 [No Abstract] [Full Text] [Related]
20. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Jüni P; Nartey L; Reichenbach S; Sterchi R; Dieppe PA; Egger M Lancet; 2004 Dec 4-10; 364(9450):2021-9. PubMed ID: 15582059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]